FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308139144> ?p ?o ?g. }

• W4308139144 endingPage "A575" @default.
• W4308139144 startingPage "A574" @default.
• W4308139144 abstract "Abstract Introduction The TSH-producing adenoma (TSHoma) prevalence in the general population is 1 to 2 cases per million, accounting for less than 2% of all pituitary adenomas. Plurihormonal tumors account for about 30% of these cases, with the most common co-secreted hormone being GH. We present the case of a patient diagnosed with TSH adenoma many years after presentation. Case Presentation A 58 year old male with a history of incidentally diagnosed pituitary microadenoma on MRI in 2007, presented in 2014 following abnormal thyroid function testing (TFT), only reported symptoms being occasional headaches. TFT was significant for elevated TSH and FT4 (TSH 4.87—Ref range: 0.27-4.2. Free T4: 1.98–Ref range 0.7-1.7). Pituitary hormone profile was remarkable for a low IGF-1 and a borderline high Alpha subunit of glycoprotein hormone. A sellar MRI confirmed a 12mm pituitary macroadenoma. He was managed conservatively on beta blockers and low dose Methimazole, owing to a stable adenoma size and poor surgical candidacy with multiple comorbidities (e. g. Atrial fibrillation). Repeat labs in 2018 showed increasing TSH (12.85), with persistent elevations of FT3, FT4 and Thyroglobulin. He had follow up TFT monitoring and surveillance MRIs until 2021 when his lesion progressed to 14 mm with mass effect on right pre chiasmatic optic nerve and adjacent internal carotid artery. The patient underwent trans sphenoidal biopsy with debulking in 2021. The biopsy showed a plurihormonal adenoma (prolactin, GH and TSH secreting). Interestingly, prolactin, GH or IGF-1 were never elevated. Following surgery, MRI showed residual 13.2×9.7 mm tumor with no mass effect. His most recent labs showed a TSH: 2.5 and FT4: 1.7. Discussion The diagnosis of a TSHoma should be considered in all centrally hyperthyroid patients, to avoid complications and undue thyroid ablation. A TSHoma must be differentiated from Resistance to Thyroid Hormone (RTH)-beta, which occurs due to mutations in the Thyroid Hormone Receptor Beta gene. Serum a-subunit concentration and Sex Hormone Binding Globulin (SHBG) concentrations are normal in RTH-beta with no TSH suppression following somatostatin analog administration. The presence of a high TSH, FT3 and FT4, in the setting of an elevated a-subunit and pituitary macroadenoma on MRI is strongly suggestive of a TSHoma. Beta blockers are recommended for symptomatic individuals however anti thyroid drug therapy is not advisable for there is risk of thyroid hormone suppression with concomitant tumor overgrowth. Definitive therapy includes trans sphenoidal tumor resection with somatostatin analog therapy to achieve euthyroidism prior to surgery. Patients should be followed up with frequent monitoring of TFT's, along with MRIs every 2-3 years. For patients with residual disease following surgery, treatment with somatostatin analogs such as Octreotide or Lanreotide is favorable as opposed to pituitary irradiation. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4308139144 created "2022-11-08" @default.
• W4308139144 creator A5001389986 @default.
• W4308139144 creator A5003747653 @default.
• W4308139144 creator A5016588426 @default.
• W4308139144 creator A5049591177 @default.
• W4308139144 creator A5056091759 @default.
• W4308139144 creator A5091716848 @default.
• W4308139144 date "2022-11-01" @default.
• W4308139144 modified "2023-09-24" @default.
• W4308139144 title "PSUN346 TSHoma: A Rare Cause of Pituitary Adenoma" @default.
• W4308139144 doi "https://doi.org/10.1210/jendso/bvac150.1192" @default.
• W4308139144 hasPublicationYear "2022" @default.
• W4308139144 type Work @default.
• W4308139144 citedByCount "0" @default.
• W4308139144 crossrefType "journal-article" @default.
• W4308139144 hasAuthorship W4308139144A5001389986 @default.
• W4308139144 hasAuthorship W4308139144A5003747653 @default.
• W4308139144 hasAuthorship W4308139144A5016588426 @default.
• W4308139144 hasAuthorship W4308139144A5049591177 @default.
• W4308139144 hasAuthorship W4308139144A5056091759 @default.
• W4308139144 hasAuthorship W4308139144A5091716848 @default.
• W4308139144 hasBestOaLocation W43081391441 @default.
• W4308139144 hasConcept C121608353 @default.
• W4308139144 hasConcept C126322002 @default.
• W4308139144 hasConcept C134018914 @default.
• W4308139144 hasConcept C2777428134 @default.
• W4308139144 hasConcept C2777433750 @default.
• W4308139144 hasConcept C2779064019 @default.
• W4308139144 hasConcept C2779318953 @default.
• W4308139144 hasConcept C2780427987 @default.
• W4308139144 hasConcept C2781100745 @default.
• W4308139144 hasConcept C2908647359 @default.
• W4308139144 hasConcept C2984496839 @default.
• W4308139144 hasConcept C2993291352 @default.
• W4308139144 hasConcept C71315377 @default.
• W4308139144 hasConcept C71924100 @default.
• W4308139144 hasConcept C90924648 @default.
• W4308139144 hasConcept C99454951 @default.
• W4308139144 hasConceptScore W4308139144C121608353 @default.
• W4308139144 hasConceptScore W4308139144C126322002 @default.
• W4308139144 hasConceptScore W4308139144C134018914 @default.
• W4308139144 hasConceptScore W4308139144C2777428134 @default.
• W4308139144 hasConceptScore W4308139144C2777433750 @default.
• W4308139144 hasConceptScore W4308139144C2779064019 @default.
• W4308139144 hasConceptScore W4308139144C2779318953 @default.
• W4308139144 hasConceptScore W4308139144C2780427987 @default.
• W4308139144 hasConceptScore W4308139144C2781100745 @default.
• W4308139144 hasConceptScore W4308139144C2908647359 @default.
• W4308139144 hasConceptScore W4308139144C2984496839 @default.
• W4308139144 hasConceptScore W4308139144C2993291352 @default.
• W4308139144 hasConceptScore W4308139144C71315377 @default.
• W4308139144 hasConceptScore W4308139144C71924100 @default.
• W4308139144 hasConceptScore W4308139144C90924648 @default.
• W4308139144 hasConceptScore W4308139144C99454951 @default.
• W4308139144 hasIssue "Supplement_1" @default.
• W4308139144 hasLocation W43081391441 @default.
• W4308139144 hasLocation W43081391442 @default.
• W4308139144 hasOpenAccess W4308139144 @default.
• W4308139144 hasPrimaryLocation W43081391441 @default.
• W4308139144 hasRelatedWork W1792821336 @default.
• W4308139144 hasRelatedWork W1981300577 @default.
• W4308139144 hasRelatedWork W2012488328 @default.
• W4308139144 hasRelatedWork W2039958784 @default.
• W4308139144 hasRelatedWork W2047253938 @default.
• W4308139144 hasRelatedWork W2049972387 @default.
• W4308139144 hasRelatedWork W2125565302 @default.
• W4308139144 hasRelatedWork W2127836255 @default.
• W4308139144 hasRelatedWork W2434702975 @default.
• W4308139144 hasRelatedWork W2983531642 @default.
• W4308139144 hasVolume "6" @default.
• W4308139144 isParatext "false" @default.
• W4308139144 isRetracted "false" @default.
• W4308139144 workType "article" @default.